Harvard Bioscience Inc
$7.95
-$0.08 (-1.00%)
$7.95Day Range$8.19
Key Statistics
Market Cap
$36.56M
Shares Outstanding
4.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 7, 2000
Round Lot
100
Locale
US
Trading Data
Day Open
$8.00
Day High
$8.19
Day Low
$7.95
Volume
19.2K
VWAP
$8.05
Prev Close
$8.03
Transactions
--
Acc. Volume
--
About Harvard Bioscience Inc
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
LABORATORY ANALYTICAL INSTRUMENTSSIC 3826339 employees84 OCTOBER HILL RD, HOLLISTON, MA, 01746(508) 893-8999IPO Dec 7, 2000US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001123494
- Composite FIGI
- BBG000C58Q08
- Share Class FIGI
- BBG001SG1ML8
- Ticker Root
- HBIO
- SIC Code
- 3826
About Harvard Bioscience Inc (HBIO) Stock
Harvard Bioscience Inc (HBIO) closed the 2026-09-18 session at $7.95, down 1.00% versus the previous close (-0.08). The stock opened at $8.00 and traded between $7.95 and $8.19 during that session. Session trading volume was 19K shares. The volume-weighted average price (VWAP) is $8.05.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Harvard Bioscience Inc has a market capitalization of $36.6 million. The company operates in the LABORATORY ANALYTICAL INSTRUMENTS industry classification. HBIO is listed on the XNAS exchange. The company employs approximately 339 people. Harvard Bioscience Inc is headquartered in HOLLISTON, MA. The recorded listing date is 2000-12-07.
On this page you can find market HBIO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the LABORATORY ANALYTICAL INSTRUMENTS sector.